Literatur
- 1 Matthes H. Alternative Therapien bei CED. Hoffmann J, Kroesen AJ, Klump B Chronisch
entzündliche Darmerkrankungen Stuttgart, New York; Thieme 2004: 199-203 (IV)
- 2
Moher D, Schulz K F, Altman D G.
The CONSORT statement: revised recommendations for improving the quality of reports
of parallel-group randomised trials.
Lancet.
2001;
357
1191-1194 (IV)
- 3
Moher D, Schulz K F, Altman D G.
The CONSORT statement: revised recommendations for improving the quality of reports
of parallel-group randomised trials.
Clin Oral Investig.
2003;
7
2-7 (IV)
- 4
Moser G, Tillinger W, Sachs G. et al .
Relationship between the use of unconventional therapies and disease-related concerns:
a study of patients with inflammatory bowel disease.
J Psychosom Res.
1996;
40
503-509 (III)
- 5
Hilsden R J, Scott C M, Verhoef M J.
Complementary medicine use by patients with inflammatory bowel disease.
Am J Gastroenterol.
1998;
93
697-701 (III)
- 6
Langhorst J, Anthonisen I, Steder-Neukamm U. et al .
Einsatz komplementärmedizinischer Therapieverfahren bei Patienten mit chronisch entzündlichen
Darmerkrankungen in Deutschland.
Z Gastroenterol.
2002;
8
641 (III)
- 7
Eisenberg D M, Kessler R C, Foster C. et al .
Unconventional medicine in the United States. Prevalence, costs, and patterns of use.
N Engl J Med.
1993;
328
246-252 (IIb)
- 8
Rawsthorne P, Shanahan F, Cronin N C. et al .
An international survey of the use and attitudes regarding alternative medicine by
patients with inflammatory bowel disease.
Am J Gastroenterol.
1999;
94
1298-1303 (III)
- 9
Heuschkel R, Afzal N, Wuerth A. et al .
Complementary medicine use in children and young adults with inflammatory bowel disease.
Am J Gastroenterol.
2002;
97
382-388 (III)
- 10
Moody G A, Eaden J A, Bhakta P. et al .
The role of complementary medicine in European and Asian patients with inflammatory
bowel disease.
Public Health.
1998;
112
269-271 (III)
- 11
Verhoef M J, Scott C MHilsden RJ.
A multimethod research study on the use of complementary therapies among patients
with inflammatory bowel disease.
Altern Ther Health Med.
1998;
4
68-71 (III)
- 12
Wu H G, Zhou L B, Shi D R. et al .
Morphological study on colonic pathology in ulcerative colitis treated by moxibustion.
World J Gastroenterol.
2000;
6
861-865 (Ib)
- 13
Chen Z S, Nie Z WSun QL.
[Clinical study in treating intractable ulcerative colitis with traditional Chinese
medicine].
Zhongguo Zhong Xi Yi Jie He Za Zhi.
1994;
14
400-402 (Ib)
- 14
Chen Z.
Treatment of ulcerative colitis with acupuncture.
J Tradit Chin Med.
1995;
15
231-233 (Ib)
- 15
Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana J L. et al .
Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with
mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study
of Crohn’s Disease and Ulcerative Colitis (GETECCU).
Am J Gastroenterol.
1999;
94
427-433 (Ib)
- 16
Kruis W, Schutz E, Fric P. et al .
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in
maintaining remission of ulcerative colitis.
Aliment Pharmacol Ther.
1997;
11
853-858 (Ib)
- 17
Rembacken B J, Snelling A M, Hawkey P M. et al .
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative
colitis: a randomised trial.
Lancet.
1999;
354
635-639 (Ib)
- 18
Ishikawa H, Akedo I, Umesaki Y. et al .
Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative
colitis.
J Am Coll Nutr.
2003;
22
56-63 (Ib)
Dr. H. Matthes
Gemeinschaftskrankenhaus Havelhöhe, Klinik für anthroposophisch erweiterte Heilkunst
Kladower Damm 221
14089 Berlin
Germany
Phone: ++ 49/30/36 50 13 43
Fax: ++ 49/30/36 50 14 55
Email: hmatthes@havelhoehe.de
